Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | ARG1 | P05089 | 2/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130500 | 1.00 | MEN1 (0.61) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9132740 | 1.00 | MEN1 (0.61) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9131600 | 1.00 | MEN1 (0.61) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9130013 | 1.00 | MEN1 (0.61) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9130042 | 1.00 | MEN1 (0.61) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9132727 | 1.00 | MEN1 (0.61) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9131137 | 0.90 | SLC1A2 (0.58) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9131149 | 0.90 | SLC1A2 (0.58) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9131854 | 0.90 | SLC1A2 (0.58) | MEN1KMT2ABLMSLC1A2ARG1 | |
| SCHEMBL9276828 | 0.86 | MEN1 (0.59) | MEN1KMT2ABLMSLC1A2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | claimed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | claimed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | claimed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | claimed |
| EP-0457324-B1 | Heterocyclic-NMDA antagonists | MERRELL DOW PHARMA (US) | 1995-12-06 | — | — | EP | claimed |
| US-5194430-A | HETEROCYCLIC-NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-16 | — | — | US | claimed |
| EP-0457324-A1 | Heterocyclic-NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-11-21 | — | — | EP | claimed |
| US-9579299-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2017-02-28 | — | — | US | disclosed |
| WO-2016027259-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2016-02-25 | — | — | WO | disclosed |
| US-20140256709-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2014-09-11 | — | — | US | disclosed |
| US-20140194514-A1 | TOPICAL FORMULATIONS | TARAXOS INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729070-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2014-05-20 | — | — | US | disclosed |
| US-5194430-A | HETEROCYCLIC-NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-16 | — | — | US | disclosed |
| CN-1061595-A | Be used as new heterocyclics of excited amino acid receptor antagonists and its production and use | AKTIEBOTAGEL ASTRA (SE) | 1992-06-03 | — | — | CN | disclosed |
| WO-1992008724-A1 | NEW HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS, PROCESSES FOR THEIR PREPARATION AND THEIR USE | AKTIEBOLAGET ASTRA (SE) | 1992-05-29 | — | — | WO | disclosed |
| CN-1056499-A | HETEROCYCLIC-NMDA ANTAGONISTS | MERRELL DOW PHARMA (US) | 1991-11-27 | — | — | CN | disclosed |
| EP-0457324-A1 | Heterocyclic-NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | MEN1 1091/4885KMT2A 1202/4885BLM 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.